KOSDAQBiotech & Pharma246250

SLSBio(Specialty Lab Solution Bio)

₩1,969 0.00%2026-11-18 close
Market Cap
₩30.2B
Turnover
₩0
Volume
0 shares
Shares out.
15.4M
PER
—
PBR
6.0×
EPS
-₩291
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Testing Revenue Rebounds, Losses Persist

On the DART-filed record, revenue has risen for four straight quarters from Q4 2025 to Q3 2026, but operating losses have continued for five quarters, so the pace of loss reduction is the next checkpoint.

  1. 1

    Annual revenue fell 52.4% year on year to KRW 3.98 billion in 2025, and the company swung to an operating loss of KRW 4.11 billion.

  2. 2

    Q3 2026 revenue reached KRW 1.66 billion, up 459.7% year on year, while an operating loss of KRW 811 million continued.

  3. 3

    Operating cash flow declined from KRW 4.03 billion in 2022 to -KRW 2.19 billion in 2025, and the debt ratio rose from 30.7% in 2024 to 47.1% in 2025.

  4. 4

    The company is positioning big pharma testing, food testing and health functional food distribution as the axes of revenue diversification.

  5. 5

    The revenue collapse in 2025 triggered listing-maintenance procedures, and the outcome of the improvement plan review remains an open uncertainty.

02

Business structure

SLSBio (Specialty Lab Solution Bio) was founded in 2007 as a company focused on new drug development support and pharmaceutical quality testing, and moved its listing to KOSDAQ in October 2023.

The business is organized into three areas: pharmaceutical quality control, new drug development support services, and in vitro diagnostic kit development.

According to a Hana Securities company report dated June 2025, pharmaceutical quality testing accounted for 94.5% of revenue and new drug development services for 5.5% based on the Q1 2025 quarterly report.

The same report cites more than 320 instruments, including HPLC, GC, AAS and IC systems, and approvals covering 31 dosage forms and 480 test items. Dailypharm reported that about KRW 7 billion of the KRW 8.37 billion revenue in 2024 came from pharmaceutical quality control.

In June 2026 the company completed technology transfer for 42 products tied to a global big pharma company and has conducted quality testing since July, according to an English-language Edaily report from October 2026.

Its health functional food distribution business has generated revenue since August 2025, and in August 2026 it received new designation as a food testing and inspection body. Unlike Samsung Biologics or Celltrion, which center on manufacturing and biosimilars, SLSBio's core is testing and inspection services.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩300M-₩1.8B−608.8%
2025Q4₩300M-₩1.4B−413.6%
2026Q1₩1B-₩1B−99.2%
2026Q2₩1.3B-₩900M−69.4%
2026Q3₩1.7B-₩800M−49.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩10.8B₩2.4B₩2.8B22.5%42.1%75.3%
2023₩9B₩1B₩1.4B11.4%10.6%32.5%
2024₩8.4B₩300M₩300M3.4%2.7%30.7%
2025₩4B-₩4.1B-₩4.9B−103.0%−64.2%47.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue went from KRW 10.8 billion in 2022 to KRW 9.02 billion in 2023 (down 16.1% year on year), KRW 8.37 billion in 2024 (down 7.2%) and KRW 3.98 billion in 2025 (down 52.4%), declining for three consecutive years from 2023 to 2025. Among 2022 to 2025, 2022 was the largest year and 2025 the smallest.

The operating margin fell from 22.5% in 2022 to 11.4% in 2023 and 3.4% in 2024, and reached -103.0% in 2025. The 2025 operating loss of KRW 4.11 billion marked a swing from profit to loss.

Profit attributable to controlling shareholders fell from KRW 2.83 billion in 2022 to KRW 1.43 billion in 2023 (down 49.3%) and KRW 336 million in 2024 (down 76.6%), before turning into a net loss of KRW 4.9 billion in 2025.

Net income including non-controlling interests showed the same direction, with a net loss of KRW 4.9 billion in 2025. The direct trigger for the revenue collapse was the operating suspension of pharmaceutical quality testing in June 2025, which Dailypharm reported at KRW 5.9 billion, or 70.7% of revenue.

Quarterly revenue was KRW 296 million in Q3 2025, KRW 341 million in Q4 2025 (up 15.3% quarter on quarter), KRW 958 million in Q1 2026 (up 180.8%), KRW 1.29 billion in Q2 2026 (up 35.2%) and KRW 1.66 billion in Q3 2026 (up 27.8%), rising for four consecutive quarters from Q4 2025 to Q3 2026.

Operating losses narrowed from KRW 1.8 billion in Q3 2025 to KRW 811 million in Q3 2026 but have continued for five consecutive quarters. Profit attributable to controlling shareholders was a loss of KRW 973 million in Q2 2026, wider than the KRW 939 million loss in Q1 2026.

The loss attributable to controlling shareholders over the latest four quarters totaled KRW 4.38 billion. Operating cash flow declined from KRW 4.03 billion in 2022 to -KRW 2.19 billion in 2025, and equity stood at KRW 7.64 billion at the end of 2025 against total liabilities of KRW 3.59 billion.

05

Industry analysis

The pharmaceutical quality testing market is driven by the volume of pharma and biopharma production and by regulatory standards. The company says requests for quality testing of biologics such as antibodies and vaccines are rising.

It also says that Q3 2026 pharmaceutical testing revenue recovered to the level of Q2 2025, before the trading suspension. According to MTN (Money Today Broadcasting), the CEO said monthly revenue reached about KRW 550 million as of September 2026, and H1 2026 cumulative revenue was KRW 2.2 billion.

Testing demand depends on re-designation by the Ministry of Food and Drug Safety, which makes the business sensitive to regulatory risk; in 2025 a failed accreditation led to an operating suspension and a sharp revenue drop.

Peers such as Samsung Biologics, Celltrion and SK Bioscience are centered on manufacturing and products, so their operating structures and metrics differ from SLSBio's. Demand for biologics testing appears linked to big pharma technology transfers and contract manufacturing flows.

In food testing, MTN reported that the imported food inspection body designation faces high regulatory barriers, with only seven approved institutions in Korea.

06

Outlook

In a September 2026 report, the company said that with monthly revenue recovering and new clients secured, its earnings normalization trend would continue from Q3. Quality testing for 42 big pharma products has been ongoing since July 2026, and the company plans to expand new orders on that base.

According to MTN, the designation as an imported food testing body is targeted for on-site inspection by the Ministry of Food and Drug Safety within 2026 and final approval by early 2027 at the latest.

An English-language Edaily report from October 2026 said the company is pursuing an application in Q1 2027, so the timing differs across reports. The ISO 17025 certification is targeted for completion in Q1 2027 with a consulting firm.

The company expects the nicotine testing market for e-cigarettes to expand once related quality testing rules take effect.

According to a Hana Securities report from June 2025, the planned diagnostic launches were a COVID-19 and influenza combo kit and influenza A/B kits in 2026, and an allergy kit and vitamin D kit in 2027. The company also announced plans to submit an improvement plan for listing maintenance in September 2026. The next checkpoint is whether quarterly revenue growth converts into operating profit.

07

Valuation

PER
—
PBR
6.0×
ROE
-61.6%
EPS
-₩291
BPS
₩330
Dividend per share
₩0

Because the loss attributable to controlling shareholders has continued for the last four quarters, the price-to-earnings ratio cannot be calculated, so earnings-based comparisons remain limited until the company returns to profit.

The price-to-book ratio sits in a premium range relative to net asset value, meaning the share price is well above book equity. With total equity of KRW 7.64 billion at the end of 2025, the current price appears to embed expectations of a future earnings recovery.

Dividend-based comparisons are limited because the dividend record is thin. Valuation comparisons will depend heavily on when revenue growth translates into an operating profit. A comparison with past PER bands would require a new run of profitable periods.

The key checkpoints are how much quarterly operating losses narrow and whether that is reflected in the operating margin in the next annual report.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Consecutive quarterly revenue growth

On the DART-filed record, revenue rose for four consecutive quarters from Q4 2025 to Q3 2026, and Q3 2026 revenue of KRW 1.66 billion was up 459.7% year on year. The company says it completed technology transfer for 42 big pharma products in June 2026 and began testing in July.

The H1 2026 cumulative revenue of KRW 2.2 billion and September monthly revenue of about KRW 550 million are company-stated figures.

Progress in business diversification

New food testing designation in August 2026 and health functional food OEM and ODM distribution, which has generated revenue since August 2025, are widening a business that had been concentrated in pharmaceutical testing.

According to MTN, the imported food inspection designation faces high barriers, with only seven approved institutions, which could make entry a differentiator. The company is targeting final approval after an on-site inspection within 2026.

Diagnostics and high-value analysis

A June 2025 Hana Securities report included plans to launch a COVID-19 and influenza combo kit and a human allergy kit.

An English-language Edaily report from October 2026 says the company is expanding impurity analysis such as nitrosamines and cell characterization, and preparing to enter nicotine testing for e-cigarettes. The ISO 17025 certification is targeted for Q1 2027.

09

Bear factors

Operating losses persist

The Q3 2026 operating loss of KRW 811 million extended a run of losses to five consecutive quarters. The Q2 2026 loss of KRW 973 million was wider than the KRW 939 million in Q1 2026. Losses have narrowed more slowly than revenue has grown, which is the core of the bearish case.

Listing-maintenance risk

Reports said the 2025 revenue decline triggered a designation as a managed stock and a formal delisting trigger. In September 2025 the KRX committee approved delisting, but re-accreditation brought an improvement period that put the delisting on hold. Listing-maintenance procedures, including an improvement plan, continued into September 2026.

Cash flow and balance-sheet shifts

Operating cash flow fell from KRW 4.03 billion in 2022 to -KRW 2.19 billion in 2025. The debt ratio rose from 30.7% in 2024 to 47.1% in 2025. Equity stood at KRW 7.64 billion at the end of 2025, against total liabilities of KRW 3.59 billion. If the thinning capital base continues, the need for additional funding could become a question.

10

Risk factors

Regulatory and accreditation risk

The testing business depends on Ministry of Food and Drug Safety re-designation. The June 2025 operating suspension halted an amount equal to 70.7% of revenue, and a non-renewal notice was disclosed in September 2025 before re-designation followed. If new criteria shortfalls arise, a similar disruption could recur. Food and imported food approvals may also shift depending on inspection results.

Client and contract concentration risk

Edaily reported in 2025 that the termination of a quality control contract tied to Wegovy was left out of the company's disclosure. Dependence on large pharmaceutical clients such as Pfizer means that changes in contract terms could flow directly into revenue. The pace at which testing for 42 big pharma products scales will shape revenue durability.

Going-concern and listing risk

The 2025 delisting review cited uncertainty about going concern tied to revenue continuity. In 2025 the company also received three penalty points as an unfaithful disclosure filer after withdrawing an asset acquisition.

With the improvement plan review unresolved and operating losses continuing, compliance with listing requirements may remain an issue.

11

What to watch next

  1. By end-December 2026

    Progress of the Ministry of Food and Drug Safety on-site inspection for imported food testing designation, per MTN reporting. Designation would mark the start of food testing revenue contribution.

  2. Q1 2027

    Target timing for the imported food inspection application and ISO 17025 certification, per the English-language Edaily report. It differs from the early-2027 final approval timing cited by MTN, so the actual schedule should be checked.

  3. After late 2026 (date not confirmed)

    KRX decision on the improvement plan. The outcome determines listing status, and the realization of diversification targets in the plan should be reviewed alongside it.

  4. Around end-March 2027 (annual report filing deadline)

    The 2026 annual report, the first periodic filing to confirm full-year 2026 revenue and operating margin including Q4. It shows whether quarterly revenue growth translated into annual profit improvement.

12

Overall view

SLSBio (Specialty Lab Solution Bio) is a biotech services company centered on pharmaceutical quality testing. Going through the 2025 operating suspension and re-designation process, its revenue fell to KRW 3.98 billion and it recorded an operating loss of KRW 4.11 billion.

Quarterly revenue rose for four consecutive quarters in 2026, reaching KRW 958 million, KRW 1.29 billion and KRW 1.66 billion in Q1 to Q3, but operating losses have continued for five consecutive quarters.

Bullish factors include the start of big pharma product testing, progress toward food and imported food testing designations, and revenue from health functional food distribution.

Bearish factors include a loss attributable to controlling shareholders of KRW 4.38 billion over the latest four quarters, operating cash flow turning negative, and a rising debt ratio. Listing-maintenance issues depend on the KRX review of the improvement plan and should be confirmed through disclosures.

The 2026 annual report will first confirm full-year revenue and operating margin, showing whether quarterly gains held up. Approval timing for imported food testing differs across reports, so the actual approval date matters.

No PER can be calculated, and the price-to-book ratio sits in a premium range, so the pace of earnings recovery is the key variable. This report is provided for information only and does not recommend any investment decision.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. calculator.io.kr
  2. zdnet.co.kr
  3. topstarnews.net
  4. stockcatcher.co.kr
  5. marketin.edaily.co.kr
  6. m.thinkpool.com
  7. zdnet.co.kr
  8. edaily.co.kr
  9. hanaw.com
  10. dailypharm.com
  11. dailypharm.com
  12. m.dailypharm.com
  13. news.mtn.co.kr
  14. kind.krx.co.kr
  15. en.edaily.co.kr
  16. news.nate.com
  17. medicopharma.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis